Go online to PeerView.com/RFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments targeting the RAS/MAPK signaling pathway have led to the first approved MEK inhibitor for the treatment of pediatric patients with symptomatic, inoperable PNs. To help lay the foundation of personalized NF1 care, this activity—based on a live event at the recent ASPHO meeting—features expert panelists sharing real-world cases to illustrate the collaborative management of NF1 tumors with highly efficacious targeted agents. The case-based conversations cover the diagnostic-treatment arc of NF1-PNs, culminating with tips and tactics arising from the clinical experience with MEK inhibitors—and going beyond to include insights on targeted strategies in other NF1 tumor settings. Watch now to start building your personalized management on a bedrock of solid science! Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations supporting modern diagnostic strategies and treatment plans incorporating targeted agents, including MEK inhibitors, for the management of pediatric patients with NF1-related PNs and other tumors; Develop evidence-based treatment plans using MEK inhibitors and other targeted therapies for the management of pediatric patients with NF1-related PNs and other tumors based on prognostic information and safety considerations; and Manage practical aspects of patient care when using innovative targeted approaches, including patient/caregiver education, monitoring, and the unique spectrum of adverse events.
View all episodes
